Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

This review highlights that while moderate physical activity benefits skin health by improving circulation and reducing stress, intense exercise or inadequate protective measures can harm the skin, emphasizing the need for sun protection and personalized care.

This meta-analysis found that patients with alopecia areata, particularly those with more extensive forms like alopecia totalis and universalis, may face a higher risk of cardiovascular disease, though no links were found with specific conditions like ischemic stroke or myocardial infarction.

This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.

In this study, researchers found that serum levels of integrin, CLEC10A, and interleukin-42 significantly differed between PCOS patients treated with infertility drugs and untreated PCOS patients when compared to healthy controls, suggesting these biomarkers could help differentiate treatment status in PCOS.

In this study, researchers found that CD4 T cells from the skin draining lymph nodes of mice with alopecia areata can transfer the disease to recipient mice, highlighting the key role of these cells and their interaction with CD8 T cells in the disease's development.

In this case study, individualized classical homeopathy was reported to effectively promote significant hair regrowth and improve emotional stability in a patient with alopecia areata, showcasing a potential holistic and sustainable alternative to conventional treatments.

This study highlights recent biological and technological strategies in anti-aging research aimed at delaying aging and related diseases, improving skin healing, and potentially restoring hair growth.

This study discusses the role of Janus kinase inhibitors in treating severe alopecia areata, highlighting their potential to personalize treatment and improve patient quality of life, while addressing concerns about disease relapse after stopping treatment and the safety of long-term use.

This study in a real-world setting found that baricitinib was effectively reducing disease severity in severe alopecia areata patients over 52 weeks, with 37.20% of participants achieving significant improvement and 72.40% experiencing mild or no adverse events.

This study found that oral tofacitinib significantly reduced alopecia severity and improved quality of life over 12 months for children with moderate to severe alopecia areata, though the authors recommend more research due to the small sample size and absence of a control group.

In this study, researchers observed that individuals with alopecia areata exhibited significant changes in scalp microbiota diversity and composition, which were linked to disease severity and inflammation markers, though it remains unclear if these microbial shifts are a cause or a result of hair loss.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This randomized control trial reported that mesenchymal stem cell-derived exosomes significantly increased hair density and thickness in patients with androgenic alopecia, with a mean increase of 35 hairs/cm² over 12 weeks compared to the placebo group, which showed minimal hair density changes.

The authors highlighted promising developments in JAK inhibitors as targeted treatments for skin diseases such as atopic dermatitis, psoriasis, and alopecia areata, noting their effectiveness and safety profiles. Recent advances also suggest potential for treating melanoma with these inhibitors.

This review article explores the pathogenesis of vitiligo and examines various therapeutic approaches, specifically highlighting the potential use of oral and topical Janus kinase inhibitors for treatment.

In this study, both topical minoxidil and latanoprost were found to improve dermoscopic features of alopecia areata, with latanoprost showing superior effectiveness; minor side effects included erythema and itching.

This review discusses the benefits and applications of low level laser therapy in cosmetic dermatology, particularly for skin conditions and pigmentation disorders, but reports no new clinical results.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This case report highlights the successful treatment of alopecia areata universalis with Baricitinib, suggesting potential long-term effectiveness of janus kinase inhibitors for this autoimmune hair loss condition.

This abstract discusses alopecia areata, highlighting its complex autoimmune pathogenesis involving immune cells and signaling molecules, and underscores the importance of accurate diagnosis and tailored management strategies, noting the need for further research to improve treatments.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

In this review, researchers examined current knowledge on alopecia areata, finding it affects approximately 2% of individuals, with a likely autoimmune and genetic basis, and highlighting its association with other medical and psychiatric conditions, although no cure currently exists.

This study found that expressions of TLR-3, TLR-7, TLR-8, and TLR-9 were significantly higher in alopecia areata patients compared to healthy controls, indicating a potential role in disease autoimmunity.

This source reviews mechanisms and existing treatments for hair aging, highlighting factors like oxidative stress and DNA repair defects that affect hair follicle and stem cell function, and discusses research limitations and future directions in the field.

This study reviews the regenerative potential and clinical applications of exosomes derived from mesenchymal stem cells in conditions like COVID-19, alopecia, skin aging, and osteoarthritis, highlighting their role as a promising tool in regenerative medicine.